wla(warner lambert) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : wla(warner lambert)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Anthony Wong who wrote (524)	2/2/1999 8:56:00 PM
From: Anthony Wong	Read Replies (2) of 942

From labpuppy.com - Weekly new prescription data on select drugs: Warner-Lambert's (WLA) Lipitor – market share of 38.7% versus 38.5% a week ago (Merck's advertising campaign, etc. for Zocor does not seem to be hurting Lipitor). Warner-Lambert's (WLA) Rezulin – market share of 8.4% versus 8.7% a week ago (concern over safety hurting market share). Warner- Lambert's (WLA) & Forrest Labs' (FRX) Celexa – market share of 5.0% versus 4.8% a week ago (continues to gain share nicely). Merck's (MRK) Zocor – market share of 22.1% versus 22.0% a week ago. Merck's (MRK) Cozaar/Hyzaar – market share of 53.4% versus 54.3% a week ago. Pfizer's (PFE) Viagra – new prescriptions rose 0.7% to 64,208. American Home Products' (AHP) Enbrel – new prescriptions increased 5.6% to 2,286 (continuing its nice ramp up). Eli Lilly's (LLY) Evista – new prescriptions rose 3.6% to 18,776. Schering-Plough's (SGP) Rebetron – new prescriptions fell 1.8% to 2,984. labpuppy.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next